\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Tetra and Cellvera will jointly expand the oral treatment, ARDS-003, with the broad-spectrum antiviral shown, Qifonda 400MG (Favipiravir)
Companies will jointly develop a combined therapeutic candidate for the rapid elimination of COVID-19 infection
The partnership aims to drive the global progression of a cutting-edge drug candidate to combat viral diseases by leveraging the expertise and resources of both companies.
New combination therapy positioned to compete with Pfizer’s flagship antiviral treatment
OTTAWA, ON, Sept. 6, 2022 /PRNewswire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in the discovery of cannabinoids and progression-derived drug derivatives, announced that they have signed an agreement with Cellvera Global Holdings LLC (“Cellvera”), for the co-progression of ARDS-003 as a combined product, with Qifenda 400MG (Favipiravir), a broad-spectrum antiviral drug in the advertising phase.
As monotherapy, compared to placebo, ARDS-003 reduced dose-dependent morbidity and mortality symptoms, which added shortness of breath after SARS-CoV-2 infection in the humanized ACE2 mouse model. mediators (i. e. , cytokines) involved in hyperinflammation and immune formula disorder after a viral infection. Other studies have also shown dose-dependent inhibition of viral replication.
Cellvera owns the rights to the original Favipiravir trademark, which has a long and verified history of protection and efficacy and which originally evolved through FujiFilm Toyama Chemical Co and was approved in Japan (2014) to treat pandemic influenza. Favipiravir is a selective viral RNA polymerase (RdRP) inhibitor with potent antiviral activity against single-stranded RNA viruses, adding coronavirus. It targets the protein needed for coronavirus replication, which prevents the virus from copying itself. The broad-spectrum antiviral drug is effective against 12 families of viruses, adding coronavirus (COVID, MERS, SARS), filovirus (EBOLA, MARBURG), flavivirus (ZIKA, WEST NILE, DENGUE), RABIES, NOROVIRUS and many others.
As new strains of the SARS-CoV-2 virus continue to emerge, initial studies on the variants of SARS-COV-2, Omicron and Delta, have shown that Favipiravir maintains its antiviral activity, demonstrating the inability of viruses to Favipiravir even with prolonged exposure to cells inflamed with the drug virus. Favipiravir remains an invaluable asset to emergency preparedness methods opposed to this ever-evolving COVID-19 virus and other potential long-term pandemics. Clinical trials of Favipiravir have shown immediate viral clearance and prevention of hospitalization when administered early in the onset of symptoms.
The parties hypothesize, based on the knowledge of Prepaire, an AI-founded in silico drug discovery platform, that a combined product of Favipiravir and ARDS-003 has the potential to enable immediate elimination of the virus and provide long-term benefits to patients. Cytokine-reducing homes of ARDS-003 would possibly save you certain effects of SARS-CoV-2 infection, such as severe lung inflammation.
Guy Chamberland, CEO and CRO of Tetra, commented: “This partnership with a global pharmaceutical company is a sign of the prospect of the active element of the drug ARDS-003. We look forward to working with Cellvera to offer this combination drug product. Improve features of the remedy for patients around the world. “
“The existing complexities of COVID-19 require multiple remedy options. By joining forces with Tetra, we look forward to bringing this additional remedy option to patients,” said Mary O’Brien, CEO of Cellvera. This collaboration with Tetra supports our marriage strategy and the progress of new combination treatments with Qifonda (Favipiravir). We share a hobby with Tetra to supply state-of-the-art medicines to combat this pandemic. We look forward to working with Guy and his team to investigate the potential of ARDS-003 and Qfienda (Favipiravir) By joining Prepaire’s spouse platform, we partner with like-minded experts from industry, academia and government, we are more prepared to pave the way for the transformation of drug discovery and progression through the application of device learning. “
About ARDS-003
ARDS-003 is a First in Human (FIH) new drug that contains the active pharmaceutical agent Onternabez, a potent and selective full agonist of the cannabinoid type 2 receptor (CB2R), an essential immunomodulatory target. modulate acute systemic inflammation and prevent sepsis, ARDS, and organ damage: ARDS represents the severe end of pulmonary disorder resulting from systemic inflammation secondary to an infectious or noninfectious clinical insult (McIntosh, 2020). Although the clinical profile of ARDS resulting from viral (COVID) or bacterial sepsis may vary, hyperinflammation involving a disordered immune reaction is a common mediator of lung damage. Preclinical studies of Tetra have shown that ARDS-003 reduces this hyperinflammatory reaction and slows the progression of the disease.
ABOUT FAVIPIRAVIR
Favipiravir, discovered and developed through FUJIFILM Toyama Chemicals (a subsidiary of FUJIFILM Corporation (FUJIY), was first approved under the Avigan logo name through Japan’s regulatory government in 2014 as a potent broad-spectrum antiviral remedy for influenza. This antiviral drug is effective against 12 families of viruses, adding coronavirus (COVID, MERS, SARS), filovirus (EBOLA, MARBURG), flavivirus (ZIKA, WEST NILE, DENGUE), RABIES, NOROVIRUS and many others. Favipiravir works by inhibiting a viral enzyme called RNA polymerase, which prevents viral replication in human cells. Favipiravir has potent antiviral activity opposite to single-stranded RNA viruses, which add coronaviruses. This is the protein to blame for the “building” of viral proteins. Favipiravir can target the protein needed for coronavirus replication, so it is highly unlikely that the virus will copy itself.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) is a leader in the discovery and progression of cannabinoid-derived drugs with an FDA- and Health Canada-approved clinical program to bring in new prescription drugs and remedies. to patients and their health care providers. Their evidence-based clinical technique has allowed them to expand a line of cannabinoid-based pharmaceuticals for a variety of medical conditions, adding pain, inflammation and oncology. With patients at the heart of its business, Tetra Bio-Pharma aims to offer rigorous clinical validation and protective knowledge for inclusion in the existing biopharmaceutical industry through regulators, physicians and insurance companies.
Sign in with Tetra: Email | | LinkedIn| | Piar Instagram
Neither TSX Exchange nor its Regulatory Service Provider (as that term is found in TSX Exchange’s policies) accepts responsibility for the adequacy or accuracy of this release.
CELLVERA:
Cellvera is a biopharmaceutical company focused on the discovery, progression and commercialization of oral treatments and surveillance equipment to address the unmet medical desires of patients with life-threatening viral diseases. Biochemistry and virology, Cellvera has created a nucleotide prodrug platform to expand applicants for new products to treat single-stranded ribonucleic acid viruses, or ssRNAs, which are a frequent cause of serious viral diseases. For more information: www. cellvera. com
PREPARATION:
PREPAiRE is an AI-based drug discovery platform, a proprietary set of rules based on deep convolutional neural networks (CNNs) and generative antagonist networks (GANs) to build biological and reactive chemical fit models that enable ligand identity for target proteins, protein-protein interactions, generate molecular structures with specific homes that combine drug capacity and capacity, as well as preparing artificial knowledge for rapid drug discovery and personalized treatment. PREPAiRE enables precision medicine by integrating whole genome sequencing with in-depth phenotyping to visualize knowledge of clinical IPS panels. The platform combines in silico prediction with high-performance rain laboratory validation in an iterative cycle that enables continuous improvement and increases the efficiency, accuracy and reliability that are critical to R
Forward-Looking Statements
Certain statements involved in this press release may contain forward-looking information. All statements, other than statements of fact, that refer to activities, occasions or progressions that the Company believes, expects or anticipates will occur or possibly occur in the long term (adding, without (limiting to, statements relating to possible acquisitions and financings) are forward-looking statements. Forward-looking statements are sometimes identified by the use of the words “possible”, “deserve”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “have the ‘intent’, ‘plan’ or ‘project’ or the negative of those words or other variations of those words or comparable terminology Forward-looking statements are subject to a number of dangers and uncertainties, many of which are beyond the Company’s ability or prediction, which could possibly cause the Company’s actual effects to differ materially from those discussed in the forward-looking statements Factors that may also may cause actual effects or occasions to differ materially from existing g expectations including, among others, the Company’s ability to offload sufficient financing to execute the Company’s business plan; competition; regulation and prices and expected and unexpected delays, the Company’s studies and progression strategies, adding the good fortune of this product or any other product, the application of the discoveries made in it, the happy and timely finishing touch and the uncertainties related to the regulatory process, the timing of clinical trials, the timing and effects of regulatory decisions or intellectual assets and other hazards disclosed in the Company’s public disclosure filing with the appropriate securities regulatory authorities. Although the Company has attempted to identify vital points that may also cause actual effects or occasions that differ materially from those described in the forward-looking statements, it is possible that there may be other points that cause actual effects or occasions that are not expected. estimated or anticipated. Readers deserve not to place undue reliance on forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release, and the Company undertakes no legal responsibility to publicly update such forward-looking statements to reflect new information, upcoming events or otherwise, unless that the applicable values so require. legislation.
View Media Download Content: https://www. prnewswire. com/news-releases/tetra-collaborates-with-cellvera-to-develop-a-potential-oral-combination-treatment-for-covid-19-patients – 301618264. html
FUENTETetra Bio-Pharma Inc.
View content to download media: http://www. newswire. ca/en/releases/archive/September2022/06/c3037. html